Discovery of Aryloxy Tetramethylcyclobutanes as Novel Androgen Receptor Antagonists
摘要:
An aryloxy tetramethylcyclobutane was identified as a novel template for androgen receptor (AR) antagonists via cell-based high-throughput screening. Follow-up to the initial "hit" established 5 as a viable lead. Further optimization to achieve full AR antagonism led to the discovery of 26 and 30, both of which demonstrated excellent in vivo tumor growth inhibition upon oral administration in a castration-resistant prostate cancer (CRPC) animal model.
Discovery of Aryloxy Tetramethylcyclobutanes as Novel Androgen Receptor Antagonists
摘要:
An aryloxy tetramethylcyclobutane was identified as a novel template for androgen receptor (AR) antagonists via cell-based high-throughput screening. Follow-up to the initial "hit" established 5 as a viable lead. Further optimization to achieve full AR antagonism led to the discovery of 26 and 30, both of which demonstrated excellent in vivo tumor growth inhibition upon oral administration in a castration-resistant prostate cancer (CRPC) animal model.
SUBSTITUTED DIAMINOPYRIMIDYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
申请人:Signal Pharmaceuticals, LLC
公开号:US20150175557A1
公开(公告)日:2015-06-25
Provided herein are diaminopyrimidyl Compounds having the following structures:
wherein X, L, R
1
, and R
2
are as defined herein, compositions comprising an effective amount of a Diaminopyrimidyl Compound, and methods for treating or preventing PKC-theta-mediated disorders, or a condition treatable or preventable by inhibition of a kinase, for example, PKC-theta.
Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
申请人:Signal Pharmaceuticals, LLC
公开号:US09156798B2
公开(公告)日:2015-10-13
Provided herein are diaminopyrimidyl Compounds having the following structures:
wherein X, L, R1, and R2 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidyl Compound, and methods for treating or preventing PKC-theta-mediated disorders, or a condition treatable or preventable by inhibition of a kinase, for example, PKC-theta.
Branched amides of L-aspartyl-D-amino acid dipeptides and compositions thereof
申请人:PFIZER INC.
公开号:EP0034876A2
公开(公告)日:1981-09-02
Amides of L-aspartyl-D-amino acid dipeptides of the formula
and physiologically acceptable cationic and acid addition salts thereof wherein Ra is methyl, ethyl, n-propyl or isopropyl and R is a branched aliphatic, alicyclic or heterocyclic member which is branched at the alpha carbon atom (the carbon atom bearing the amide nitrogen atom) and also branched again at one or both of the beta carbon atoms, are potent sweeteners which are free from undesirable flavour qualities and of high stability in conventional food processing. Sweetening compositions and sweetened edible compositions of such amides are also claimed
式中 L-天冬氨酰-D-氨基酸二肽的酰胺类
及其生理上可接受的阳离子盐和酸加成盐,其中 Ra 为甲基、乙基、正丙基或异丙基,R 为支链脂环族、脂环族或杂环族成员,该成员在 α 碳原子(含酰胺氮原子的碳原子)上有支链,在一个或两个β碳原子上也有支链。这种酰胺的甜味组合物和甜味可食用组合物也已申请专利。
PROCESS FOR THE PREPARATION OF SUBSTITUTED DIAMINOPYRIMIDYL COMPOUNDS
申请人:Signal Pharmaceuticals, LLC
公开号:EP3736268A1
公开(公告)日:2020-11-11
The invention provides a method for preparing a compound of formula (I):
comprising contacting a compound of formula (Ia)
or a compound of formula (Ic)
with R1-L-NH2, in an organic solvent, in the presence of a base, under conditions as defined herein. Also provided are reaction intermediates involved in said method as defined herein.